1 Wang L, et al. BMJ Open 2022;12:e055742. doi:10.1136/bmjopen-2021-055742Open access Therapy of genomic unstable solid tumours (WHO grade 3/4）in clinical stage III/IV using individualised neoantigen tumour peptides- INP trial (individualised neoantigen tumour peptides immunotherapy): study protocol for an open- label, non- randomised, prospective, single- arm trial Ling Wang ,1 Jiaxi Tang ,2 Xia Chen,3 Juan Zhao,1 Wanyan Tang,1 Bin Liao,1 Weiqi Nian1,4 To cite: Wang L, Tang J, Chen X, et al. Therapy of genomic unstable solid tumours (WHO grade 3/4）in clinical stage III/IV using individualised neoantigen tumour peptides- INP trial (individualised neoantigen tumour peptides immunotherapy): study protocol for an open- label, non- randomised, prospective, single- arm trial. BMJ Open 2022;12:e055742.